Drugs / Biotin Labeled Red Blood Cells
Biotin Labeled Red Blood Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04426591 | Oct 2021 → Apr 2025 | sickle cell disease | Marianne Yee | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biotin Labeled Red Blood Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04426591 ↗ |
| Known as | B-RBC | “Biotin-labeled RBCs (B-RBC) were analyzed by flow cytometry at 15 minutes, 24 hours, and weekly through 16 weeks after transfusion.” PMID 42018645 ↗ Jul 2026 |
| Known as | BioRBC | “The biotin-labeled RBC (BioRBC) is transfused along with the remainder of the RBC unit (unlabeled volume).” NCT04426591 ↗ |